Solution structure of the catalytic domain of human stromelysin-1 complexed to a potent, nonpeptidic inhibitor.Li, Y.C., Zhang, X., Melton, R., Ganu, V., Gonnella, N.C.
(1998) Biochemistry 37: 14048-14056
- PubMed: 9760240
- DOI: 10.1021/bi981328w
- PubMed Abstract:
- The NMR Structure of the Inhibited Catalytic Domain of Human Stromelysin-1
Gooley, P.R.,O'Connell, J.F.,Marcy, A.I.,Cuca, G.C.,Salowe, S.P.,Bush, B.L.,Hermes, J.D.,Esser, C.K.,Hagmann, W.K.,Springer, J.P.,Johnson, B.A.
(1994) Nat.Struct.Mol.Biol. 1: 111
The full three-dimensional structure of the catalytic domain of human stromelysin-1 (SCD) complexed to a novel and potent, nonpeptidic inhibitor has been determined by nuclear magnetic resonance spectroscopy (NMR). To accurately mimic assay condition ...
The full three-dimensional structure of the catalytic domain of human stromelysin-1 (SCD) complexed to a novel and potent, nonpeptidic inhibitor has been determined by nuclear magnetic resonance spectroscopy (NMR). To accurately mimic assay conditions, the structure was obtained in Tris buffer at pH 6.8 and without the presence of organic solvent. The results showed that the major site of enzyme-inhibitor interaction occurs in the S1' pocket whereas portions of the inhibitor that occupy the shallow S2' and S1 pockets remained primarily solvent exposed. Because this relatively small inhibitor could not deeply penetrate stromelysin's long narrow hydrophobic S1' pocket, the enzyme was found to adopt a dramatic fold in the loop region spanning residues 221-231, allowing occupation of the solvent-accessible S1' channel by the enzyme itself. This remarkable conformational fold at the enzyme binding site resulted in constriction of the S1' loop region about the inhibitor. Examination of the tertiary structure of the stromelysin-inhibitor complex revealed few hydrogen-bonding or hydrophobic interactions between the inhibitor and enzyme that can contribute to overall binding energy; hence the resultant compact structure may in part account for the relatively high potency exhibited by this inhibitor.
Novartis Pharmaceuticals Corporation, Summit, New Jersey 07901, USA.